Opko Health Inc (OPK)

[junewong]

Recent launches in the renal market have typically been associated with slow uptake, largely hampered by limited market access. This is also true for Opko's Rayaldee, a vitamin D3 prohormone launched in November 2016. However, Opko also faces other challenges as well, including an inferior promotional rate (compared to phosphate binders and Sensipar), low familiarity among nephrologists, and a lack of a perceived unmet need for the product. Indeed, just 6% of the surveyed nephrologists reported any trial of Rayaldee at the four month mark and two-thirds have not had any contact with a sales representative since the product was launched.

https://goo.gl/xUIOfW